Journal of International Oncology››2019,Vol. 46››Issue (1): 17-21.doi:10.3760/cma.j.issn.1673-422X.2019.01.004
Previous ArticlesNext Articles
Chen Yu, Li Qiang, Zhang Cong, Li Shijie
Received:
2018-07-05Online:
2019-01-08Published:
2019-04-03Contact:
Li Shijie E-mail:735405661@qq.comChen Yu, Li Qiang, Zhang Cong, Li Shijie. Effects of Xiaoaiping injection assisted TP regimen on immune status, adverse reactions and quality of life in the treatment of advanced NSCLC[J]. Journal of International Oncology, 2019, 46(1): 17-21.
[1] 龚红卫, 李成银, 罗秀丽. 胎盘多肽注射液辅助治疗老年晚期非小细胞肺癌的临床研究[J]. 医学临床研究, 2016, 33(4): 701-702, 705. DOI: 10.3969/j.issn.16717171.2016.04.023. [2] Di Maio M, Chiodini P, Georgoulias V, et al. Metaanalysis of singleagent chemotherapy compared with combination chemotherapy as secondline treatment of advanced non-small-cell lung cancer[J]. J Clin Oncol, 2016, 27(11): 1836-1843. DOI: 10.1200/JCO.2008.17.5844. [3] 麦泽锋. 消癌平注射液联合多西他赛治疗晚期非小细胞肺癌的临床观察[J]. 国际肿瘤学杂志, 2017, 44(7): 557-558. DOI: 10.3760/cma.j.issn.1673-422X.2017.07.021. [4] Ettinger DS, Akerley W, Borghaei H, et al. Nonsmall cell lung cancer, version 2.2013[J]. J Natl Compr Canc Netw, 2013, 11(6): 645-653. [5] 张贺龙. 实体瘤疗效评价标准及演变[J]. 现代肿瘤医学, 2010, 18(5): 839-841. DOI: 10.3969/j.issn.1672-4992.2010.05.01. [6] 宋琳, 殷东风, 唐广义. 症状、KPS对非小细胞肺癌“稳定”疗效判定标准影响[J]. 辽宁中医药大学学报, 2014, 16(7): 91-93. DOI: 10.13194/j.issn.1673-842x.2014.07.031. [7] Hirsh V, Ko A, Pilot R, et al. Weekly nabpaclitaxel in combination with carboplatin as firstline therapy in patients with advanced nonsmallcell lung cancer: analysis of safety and efficacy in patients with diabetes[J]. Clin Lung Cancer, 2016, 17(5): 367-374. DOI: 10.1016/j.cllc.2016.04.002. [8] Fiteni F, Anota A, Bonnetain F, et al. Healthrelated quality of life in elderly patients with advanced nonsmall cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy[J]. Eur Respir J, 2016, 48(3): 861-872. DOI: 10.1183/13993003.016952015. [9] 姚俊. 消癌平注射液联合化疗干预非小细胞肺癌晚期有效性和安全性研究[J]. 现代中西医结合杂志, 2016, 25(24): 2706-2708. DOI: 10.3969/j.issn.1008-8849.2016.24.031. [10] 李清林, 程斌. 消癌平注射液联合GP化疗方案治疗晚期非小细胞肺癌临床疗效研究[J]. 中华中医药学刊, 2016, 34(4): 785-787. DOI: 10.13193/j.issn.1673-7717.2016.04.004. [11] 胡晓琳, 刘喜松, 陈细定. 消癌平注射液联合吉西他滨和卡铂治疗ⅢB和Ⅳ期非小细胞肺癌的临床评价[J]. 药物评价研究, 2017, 40(2): 266-269. DOI: 10.7501/j.issn.1674-6376.2017.02.027. [12] 叶璐, 付波. 消癌平注射液对晚期非小细胞肺癌TP方案化疗患者近期增效减毒的作用[J]. 山西医药杂志, 2017, 46(10): 1189-1191. DOI: 10.3969/j.issn.0253-9926.2017.10.021. [13] 蒋晓芳, 林山. 扶正中药颗粒联合GC化疗方案对晚期非小细胞肺癌患者的免疫功能及近期疗效的影响分析[J]. 辽宁中医杂志, 2017, 44(4): 143-145. DOI: 10.13192/j.issn.1000-1719.2017.04.048. [14] 张长理, 李桂文. CT引导下射频消融对非小细胞肺癌患者免疫功能的影响[J]. 标记免疫分析与临床, 2016, 23(7): 763-765. DOI: 10.11748/bjmy.issn.1006-1703.2016.07.014. [15] 刘赞. 消癌平注射液联合新辅助化疗对NSCLC患者免疫功能的影响[J]. 医学临床研究, 2016, 33(11): 2178-2180. DOI: 10.3969/j.issn.1671-7171.2016.11.034. [16] 李心国, 姜晓静. 消癌平注射液联合GP方案治疗晚期非小细胞肺癌的临床观察[J]. 中国临床医生杂志, 2016, 44(10): 62-64. DOI: 10.3969/j.issn.2095-8552.2016.10.022. |
[1] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[2] | Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113. |
[3] | Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104. |
[4] | Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei.Current status of research on exosomes in malignancies[J]. Journal of International Oncology, 2023, 50(8): 484-488. |
[5] | Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347. |
[6] | Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367. |
[7] | Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86. |
[8] | Chen Yi, Han Liang, Cai Li.Multivariate analysis of chemotherapy induced oral mucositis in patients with head and neck tumors[J]. Journal of International Oncology, 2022, 49(9): 521-525. |
[9] | Chu Xuelei, Mao Yun, Xue Peng, Li Linlu, Chen Meichi, Yuan Chunsheng, Qin Xiaoyan, Zhu Shijie.Effects of chemotherapy dose intensity on short-term efficacy in patients with advanced colon cancer: a study based on real-world data[J]. Journal of International Oncology, 2022, 49(7): 408-415. |
[10] | Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer[J]. Journal of International Oncology, 2022, 49(5): 276-281. |
[11] | Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu.Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(3): 140-145. |
[12] | Lao Zheng, Tu Wenyong, Xu Xuanli, Zhang Lin, Shao Ziyang, Shi Huifeng.Nimotuzumab combined with definitive radiotherapy for inoperable locally advanced oral and maxillofacial squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(11): 665-670. |
[13] | Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin.Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis[J]. Journal of International Oncology, 2022, 49(1): 45-50. |
[14] | Long Xin, Wu Han, Peng Jin, Zhou Fuxiang.Systemic therapy of advanced biliary tract cancer[J]. Journal of International Oncology, 2021, 48(5): 302-307. |
[15] | Liu Saisai, Yuan Dongya.Regulation of IL-35, IL-39 and IL-27 in tumor microenvironment[J]. Journal of International Oncology, 2021, 48(4): 212-215. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||